608 Results for "

binding peptide

" in MedChemExpress (MCE) Product Catalog:
Products (608)

608 Results for "binding peptide" in MCE Product Catalog:

Art. -Nr.: HY-182539
CAS. Nr.: 1202877-06-2
Target:  

CGRP Receptor

Forschungsgebiete:  

Others Neurological Disease

DD04107 is a neuronal exocytosis inhibitor with a rat Syt1-C2B domain binding Kd of 2.4 μM. DD04107 interferes with synaptobrevin-syntaxin-SNAP-25 complex formation and Syt1-SNARE complex interaction to block α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons. DD04107 blocks inflammatory ion channel recruitment to nociceptor plasma membranes. DD04107 can be used for the research of chronic inflammatory pain, neuropathic pain, osteosarcoma pain, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, inflammatory pain .
loading...
    loading...
Art. -Nr.: HY-P10861
Target:  

Tau Protein

Forschungsgebiete:  

Neurological Disease

RI-AG03 is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 can be used for research on tau-related diseases such as Alzheimer's disease .
loading...
    loading...
Art. -Nr.: HY-P10861A
Target:  

Tau Protein

Forschungsgebiete:  

Neurological Disease

RI-AG03 acetate is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 acetate inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 acetate mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 acetate suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 acetate can be used for research on tau-related diseases such as Alzheimer's disease .
loading...
    loading...
Art. -Nr.: HY-P11457
CAS. Nr.: 2378579-44-1
Target:  

Bacterial

Forschungsgebiete:  

Infection

cCBD-LL37 is a chimeric antimicrobial peptide modified with a collagen-binding domain (cCBD) (TKKTLRT). cCBD-LL37 has improved retention on collagen after PBS washing and varying electrostatic conditions. cCBD-LL37 binds to collagen involves both specific and non-specific interactions, initiated by long-range electrostatic forces that transitions to close range or hydrophobic interactions. cCBD-LL37 has potent antimicrobial activity with improved structural stability under different ionic strengths and pH conditions (pH 5.5-8). cCBD-LL37 can be used for biomaterials like collagen-based wound dressings research .
loading...
    loading...
Art. -Nr.: HY-P11582
Target:  

Bacterial

Forschungsgebiete:  

Infection

CyLip-20 is a cyclic lipopeptide antimicrobial peptide that targets Gram-positive and Gram-negative bacteria. CyLip-20 exhibits low hemolytic activity and mild in vivo toxicity. CyLip-20 disrupts the integrity of bacterial outer membrane, inner membrane and cytoplasmic membrane by binding to bacterial lipopolysaccharide (LPS), triggering membrane permeabilization, depolarization and leakage of intracellular contents, and inhibits bacterial biofilm formation. In animal models, CyLip-20 reduces the bacterial load in skin wounds of mice infected with MRSA, promotes wound healing, decreases the levels of inflammatory cytokines and reduces inflammatory cell infiltration. CyLip-20 can be used in research related to MRSA skin wound infections .
loading...
    loading...
Art. -Nr.: HY-135446
CAS. Nr.: 141595-53-1
Target:  

Endothelin Receptor

Forschungsgebiete:  

Cardiovascular Disease Endocrinology

BQ-610 is a selective antagonist of the endothelin A receptor (ETA receptor). BQ-610 specifically blocks the ETA receptor, competitively inhibiting the binding of endothelin-1 (ET-1) (a vasoconstrictive peptide) to the receptor, thereby blocking the effects of ET-1 such as vascular smooth muscle contraction, cell mitosis, and inhibition of hormone secretion. BQ-610 significantly alleviates cerebral vasospasm in rabbits. BQ-610 blocks the bronchial epithelial and pulmonary vascular cell proliferation caused by cigarette smoke in rat models. BQ-610 can delay the natural luteal regression in the cow's uterus. BQ-610 can be used for research on vasospasm, abnormal cell proliferation, and reproductive endocrine disorders .
loading...
    loading...
Art. -Nr.: HY-183488
CAS. Nr.: 1207092-73-6
Synonyms: RRRRRRRRRCCLGIPEQEY
Target:  

Apoptosis PARP

Forschungsgebiete:  

Cancer

R9-caPep (RRRRRRRRRCCLGIPEQEY) is a cell-penetrating peptide derived from proliferating cell nuclear antigen (PCNA). R9-caPep selectively blocks the interactions between PCNA and FEN1, as well as between PCNA and LIGI, while preserving the binding of POLD3 to PCNA. R9-caPep interferes with DNA synthesis and homologous recombination-mediated double-strand DNA break repair, inducing S-phase arrest, DNA damage accumulation, and apoptosis. R9-caPep inhibits the growth of tumor volume and weight of neuroblastoma in nude mice . R9-caPep can be used in research related to neuroblastoma and triple-negative breast cancer .
loading...
    loading...
Art. -Nr.: HY-P11246
CAS. Nr.: 3057097-31-8
Target:  

RXFP Receptor

Forschungsgebiete:  

Metabolic Disease

A13:B7-24-GG is an engineered analogue of insulin-like peptide 5 (INSL5), a selective RXFP4 agonist with a Ki value of 2.29 nM. A13:B7-24-GG has an extremely low binding affinity for RXFP3 (Ki = 602.56 nM) and an inhibitory effect on cAMP (EC50) of 1.17 nM. Activation of RXFP4 by A13:B7-24-GG leads to the recruitment of β-Arrestin2, with an EC50 of 22.39 nM. A13:B7-24-GG can be used for research on chronic constipation .
loading...
    loading...
Art. -Nr.: HY-P11902
Forschungsgebiete:  

Cancer

IRS1 is an integrin-targeted, ROS-responsive self-assembling peptide prodrug molecule with selective anti-cancer activity against integrin-overexpressing tumor cells. IRS1 contains an RGD motif for integrin binding, can covalently bind to DR4/DR5, and promotes DR4/DR5 aggregation. After oxidation by ROS, IRS1 undergoes a morphological transition from nanoparticles to nanofibers, exposes the pharmacophore of Chlorambucil (HY-13593), disrupts cell membrane integrity, activates the extrinsic apoptosis pathway, and can penetrate and inhibit the three-dimensional uveal melanoma spheroid model. IRS1 can be used for the research of uveal melanoma .
loading...
    loading...
Art. -Nr.: HY-W010697S
Cholesteryl linoleate-d11 is the d11-labeled Cholesteryl linoleate (HY-W010697). Cholesteryl linoleate is a cholesteryl ester with antibacterial activity that is present in low-density lipoprotein (LDL) particles, human nasal fluid, and respiratory epithelial secretions. Cholesteryl linoleate is oxidized by 12/15-lipoxygenase in macrophages and participates in selective uptake and efflux via LDL receptor-related protein. Cholesteryl linoleate does not induce endothelial adhesion molecule expression, nor does it induce monocyte binding to endothelial cells. Cholesteryl linoleate liposomal formulations inhibit the growth of multiple bacteria at physiological nasal fluid concentrations and act synergistically with antimicrobial peptides. Cholesteryl linoleate is useful for research related to atherosclerosis and bacterial infections .
loading...
    loading...
Art. -Nr.: HY-W012572
CAS. Nr.: 351-50-8
Forschungsgebiete:  

Infection Metabolic Disease

D-Histidine is an anti-biofilm agent that targets bacterial quorum sensing systems (such as RhlI/RhlR pathway) and has antibacterial activity. D-Histidine works by non-covalently binding to bacterial regulatory factors or copper ion complexes, selectively inhibiting bacterial biofilm formation and motility. D-Histidine downregulates quorum sensing-related gene expression, reduces the synthesis of virulence factors (such as alginate and proteases), and interferes with bacterial membrane stability, inhibiting biofilm formation, promoting the disintegration of mature biofilms, and enhancing antibiotic sensitivity. D-Histidine is also an efficient catalyst for the salt-induced peptide formation (SIPF) reaction, which promotes the condensation of amino acids to form dipeptides (such as dialanine and dilysine) by forming a complex with copper ions (Cu 2+) .
loading...
    loading...
Art. -Nr.: HY-W012572A
CAS. Nr.: 328526-86-9
Forschungsgebiete:  

Infection Metabolic Disease

D-Histidine hydrochloride hydrate is an anti-biofilm agent that targets bacterial quorum sensing systems (such as RhlI/RhlR pathway) and has antibacterial activity. D-Histidine hydrochloride hydrate works by non-covalently binding to bacterial regulatory factors or copper ion complexes, selectively inhibiting bacterial biofilm formation and motility. D-Histidine hydrochloride hydrate downregulates quorum sensing-related gene expression, reduces the synthesis of virulence factors (such as alginate and proteases), and interferes with bacterial membrane stability, inhibiting biofilm formation, promoting the disintegration of mature biofilms, and enhancing antibiotic sensitivity. D-Histidine hydrochloride hydrate is also an efficient catalyst for the salt-induced peptide formation (SIPF) reaction, which promotes the condensation of amino acids to form dipeptides (such as dialanine and dilysine) by forming a complex with copper ions (Cu 2+) .
loading...
    loading...
Art. -Nr.: HY-108556AR
CAS. Nr.: 2387505-58-8
RWJ-56110 dihydrochloride (Standard) is the analytical standard of RWJ-56110 (dihydrochloride) (HY-108556A). This product is intended for research and analytical applications. RWJ-56110 dihydrochloride is a potent, selective, peptide-mimetic inhibitor of PAR-1 activation and internalization (binding IC50=0.44 uM) and shows no effect on PAR-2, PAR-3, or PAR-4. RWJ-56110 dihydrochloride inhibits the aggregation of human platelets induced by both SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM), quite selective relative to U46619 (HY-108566). RWJ-56110 dihydrochloride blocks angiogenesis and blocks the formation of new vessels in vivo. RWJ-56110 dihydrochloride induces cell apoptosis .
loading...
    loading...
Art. -Nr.: HY-15191B
CAS. Nr.: 1228178-73-1
Reinheit:  98.03%
Synonyms: (S)-BI-97C1
Target:  

Bcl-2 Family

Forschungsgebiete:  

Cancer

(S)-Sabutoclax ((S)-BI-97C1), an optically pure apogossypol derivative, is pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. (S)-Sabutoclax (Compound II) inhibits the binding of BH3 peptides to Bcl-XL, Bcl-2, Mcl-1, and Bfl-1 with IC50 values of 0.31, 0.32, 0.20, and 0.62 μM, respectively. (S)-Sabutoclax also potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC50 values of 0.13, 0.56, and 0.049 μM, respectively. (S)-Sabutoclax can be used for the research of apoptosis-based therapies against cancer .
loading...
    loading...
Art. -Nr.: HY-DY1088
CAS. Nr.: 75350-46-8
Synonyms: N-(5-Fluoresceinyl)maleimide (solution)
Fluorescein-5-maleimide (solution) (N-(5-Fluoresceinyl)maleimide (solution)) is a fluorescent dye. Fluorescein-5-maleimide can be used to detect the redox state of thiols in eukaryotic cells. Fluorescein-5-maleimide can label peptides and is used to detect negatively charged nanoparticles. Fluorescein-5-maleimide can also label actin to explore its interaction with cardiac myosin-binding protein C (cMyBP-C), which helps in developing small molecule modulators for heart failure. Fluorescein-5-maleimide can screen mutant proteins that contain cysteine residues. The excitation wavelength of Fluorescein-5-maleimide is 494 nm, and the emission wavelength is 519 nm .

Solvent and concentration: DMSO: 10 mM
loading...
    loading...
Art. -Nr.: HY-P11107
CAS. Nr.: 2375823-45-1
Target:  

Apoptosis TNF Receptor

Forschungsgebiete:  

Inflammation/Immunology Cancer

RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (Kd = 3.5 μM). RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF) .
loading...
    loading...
Art. -Nr.: HY-P11590
Target:  

EGFR

Forschungsgebiete:  

Cancer

WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a KD of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .
loading...
    loading...
Art. -Nr.: HY-P11842
Target:  

DNA/RNA Synthesis

Forschungsgebiete:  

Cancer

Ac-HFKLYWPPFLGS-NH2 is a RMI1/2 heterodimer inhibitor with an IC50 of 99 nM and antiproliferative activity. Ac-HFKLYWPPFLGS-NH2 binds competitively at the FANCM-RMI interaction interface, mimics native FANCM MM2 domain hydrophobic interactions, and adopts a unique binding pose with additional protein interactions. Ac-HFKLYWPPFLGS-NH2 induces antiproliferative effects in ALT-positive osteosarcoma cells. Ac-HFKLYWPPFLGS-NH2 shows limited stability toward α-chymotrypsin-mediated enzymatic degradation in vitro. Ac-HFKLYWPPFLGS-NH2 lacks inherent cell permeability, requiring conjugation to a cell-penetrating peptide for intracellular delivery. Ac-HFKLYWPPFLGS-NH2 can be used for the research of ALT-positive osteosarcoma .
loading...
    loading...
Art. -Nr.: HY-L932V0
2,000,000 compounds

Macrocyclic compounds (≥12-atom cyclic small molecules/peptides) have unique physicochemical properties. They form preorganized conformations with high binding affinity/selectivity, target traditional small-molecule-inaccessible proteins, and bridge small-molecule drugs and biological agents. As key protein phosphorylation enzymes, kinases are linked to tumors, COPD, etc., and are critical therapeutic targets. Traditional small-molecule kinase inhibitors lack selectivity, causing off-target toxicity, low bioavailability, and acquired resistance. Macrocycles’ semi-rigid structure restricts conformations, boosts binding selectivity, optimizes pharmacokinetics, and makes macrocyclization a core kinase inhibitor optimization strategy.

Thousands of bioactive macrocycles were curated from ChEMBL. Via Transformer, macrocyclization was converted into a chemical language translation task, enabling end-to-end macrocycle generation from linear precursors with simplified inputs. Macformer achieves efficient, automated linear molecule macrocyclization via deep learning; generated macrocycles have diversity, novelty, biocompatibility, and cover broader chemical space.

MCE collected thousands of marketed/clinical kinase inhibitors, using their fragments for macrocyclization to generate derivatives. After evaluating synthetic accessibility and physicochemical properties, a million-scale virtual macrocyclic library was built for kinase-related virtual and AI-driven screening.

Art. -Nr.: HY-L932V
2,000,000 compounds

Macrocyclic compounds (≥12-atom cyclic small molecules/peptides) have unique physicochemical properties. They form preorganized conformations with high binding affinity/selectivity, target traditional small-molecule-inaccessible proteins, and bridge small-molecule drugs and biological agents. As key protein phosphorylation enzymes, kinases are linked to tumors, COPD, etc., and are critical therapeutic targets. Traditional small-molecule kinase inhibitors lack selectivity, causing off-target toxicity, low bioavailability, and acquired resistance. Macrocycles’ semi-rigid structure restricts conformations, boosts binding selectivity, optimizes pharmacokinetics, and makes macrocyclization a core kinase inhibitor optimization strategy.

Thousands of bioactive macrocycles were curated from ChEMBL. Via Transformer, macrocyclization was converted into a chemical language translation task, enabling end-to-end macrocycle generation from linear precursors with simplified inputs. Macformer achieves efficient, automated linear molecule macrocyclization via deep learning; generated macrocycles have diversity, novelty, biocompatibility, and cover broader chemical space.

MCE collected thousands of marketed/clinical kinase inhibitors, using their fragments for macrocyclization to generate derivatives. After evaluating synthetic accessibility and physicochemical properties, a million-scale virtual macrocyclic library was built for kinase-related virtual and AI-driven screening.